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Abstract
Somatic mutation calling from next-generation sequencing data remains a challenge due to the difficulties of distinguishing
true somatic events from artifacts arising from PCR, sequencing errors or mis-mapping. Tumor cellularity or purity, sub-
clonality and copy number changes also confound the identification of true somatic events against a background of
germline variants. We have developed a heuristic strategy and software (http://www.qcmg.org/bioinformatics/qsnp/) for
somatic mutation calling in samples with low tumor content and we show the superior sensitivity and precision of our
approach using a previously sequenced cell line, a series of tumor/normal admixtures, and 3,253 putative somatic SNVs
verified on an orthogonal platform.
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Introduction
The declining cost of next-generation sequencing is enabling an
increasing number of tumor sequencing studies [1–3], providing
new insights into the mutations driving tumorigenesis. These large-
scale efforts are redefining the role of known oncogenes and tumor
suppressor genes, identifying new candidate driver genes and
providing insights into the mutational mechanisms at play in
different tumor types [4,5]. Accurate somatic mutation calling is
paramount in these studies.
Despite this growing demand for accurate somatic mutation
calls in cancer studies, mutation calling from next-generation
sequencing data remains challenging. Early cycle PCR-induced
errors, polymerase slippage [6] and the mis-mapping of reads due
to homology to multiple genomic regions are some of the most
common sources of false positive calls. Inadequate sequence depth
in the matched normal sample can also result in germline variants
being incorrectly identified as somatic mutations (false positives).
Finally, tumor heterogeneity and purity further confound accurate
somatic mutation calling as increased tumor heterogeneity and
decreased purity result in lower mutant allele ratios that can make
it difficult to distinguish true mutations from background (false
negative error). In solid tumors, purity varies widely with some
tumor samples having less than 10% tumor content. Many low
purity tumor samples have been excluded from somatic mutation
analysis to date due to the analytical challenges associated with
accurately calling mutations in these samples and the expected
high false negative rate. To keep the sensitivity of the analysis at
desired levels, there is a risk of calling an increasing number of
false positives.
Several software programs have been developed for variant and
somatic mutation calling, including GATK [7], Strelka [8],
diBayes (Applied Biosystems BioScopeTM software), SomaticSni-
per [9], VarScan 2 [10] and SNVMix [11]. For cancer genome
analysis and to identify somatic events, a tumor sample is
compared to its matched normal sample. Current software tools
differ in important ways by either performing single or joint
sample analysis of the tumor/matched normal sample pair, and by
either using Bayesian or heuristic approaches (Table 1). GATK
was initially developed in the context of the 1000 Genomes Project
[12] to enable variant discovery and genotyping from next-
generation sequencing data. GATK performs single sample
analysis only. A tumor and matched normal sample pair are thus
genotyped independently and somatic events are determined by
subtracting calls in the normal from those in the tumor sample. In
contrast, Strelka, SomaticSniper and VarScan 2 perform joint
sample analysis of a tumor/normal pair and either model tumor as
a mixture of normal sample with somatic variation (Strelka),
calculate joint diploid genotype likelihoods using the MAQ
genotype model (SomaticSniper) or compare read count distribu-
tions between the two samples using Fisher’s exact test (VarScan2).
Importantly, due to the different statistical models employed,
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current somatic mutation callers differ in the number of somatic
mutation calls and in their overlap. In addition, many somatic
mutation callers use a series of post-call filtering steps that further
affect the number and type of final mutation calls. Some of these
tools also allow analysis of small indels, germline variants and copy
number variations (Table 1).
There have not been, however, any detailed investigations of
the effects of reduced tumor cellularity or purity on the accuracy
and sensitivity of somatic mutation calling, although a recent
software, MuTect, has been designed especially with subclonal
mutations in mind [13]. A number of factors compromise somatic
mutation calling in low purity tumors. As sequence coverage and
tumor purity decrease, the effects of allele sampling confound the
accurate assessment of allele distributions and thus compromise
statistical models for determining potential variant sites of interest.
Secondly, depending on the statistic models used, low frequency
mutations may or may not trigger a variant call resulting in
differences in the number and type of mutations called between
different callers. Our interests in pancreatic adenocarcinomas
where over 70% of tumors are of less than 40% purity due to
desmoplastic stroma and despite enrichment by histology-guided
macrodissection [14] have motivated us to determine optimal
strategies for somatic point mutation calling in these tumors. To
this end, several mutation calling strategies were tested and
extensive verification was performed, in which true positive and
false positive mutation calls were inspected to identify common
error sources. A heuristics-based single nucleotide variant caller,
qSNP, was then implemented using these empirically determined
features. Its performance was directly assessed in samples of
varying purity that were generated by mixing a tumor cell line and
its matched normal sample at varying proportions and sequencing
each mixture. The decay in sensitivity as purity decreased in these
mixtures was assessed and the performance of our caller was
compared to that of two others. Finally, its performance was
benchmarked against the COLO-829 cell line, previously
sequenced and analyzed by Pleasance et al. [4].
Results
Our somatic mutation calling strategy has been designed to
maximize sensitivity in light of low tumor purity. Iterative rounds
of verification using benchtop amplicon-based sequencing were
performed to develop and refine post-processing checks to control
the false discovery rate. The following considerations informed the
design of our mutation calling strategy and its software
implementation, qSNP.
Joint analysis of the tumor and matched normal sample
qSNP considers sequence data in Binary Sequence Alignment/
Map (BAM) format [15] from both tumor and matched normal
samples jointly. Classification into germline and somatic calls
follows a number of simple rules that were designed to
accommodate for the expected low mutant allele ratio in low
purity tumors (Table 2).
Maximize sensitivity of mutation calling
qSNP currently triggers a variant call if a minimum of 3 reads of
the same, non-reference allele are found. We found that this
minimum evidence requirement ensures that a variant call is
triggered even in regions where Poisson sampling of alleles may
have confounded the observed allele distributions. As sequence
depth increases, so does the minimum read requirement. At
coverage over 206a minimum of 4 mutant reads are required and
above 506 a minimum of 5% of mutant reads or a minimum of
2.5% mutant reads if reads are on both strands. In addition, the
base qualities of the variant reads must be at least 10% of the sum
of base qualities at the position or at least 5% of the sum of base
qualities if reads are found on both strands and coverage is over
506. To determine whether the position is homozygous or
heterozygous, the two most common alleles are determined. If
both alleles match the evidence criteria above, the position is
considered heterozygous, and if not, homozygous.
Post-processing checks to control the false discovery rate
Various factors influence the confidence in a somatic mutation
call, including sequence depth in tumor and matched normal, base
qualities of alleles, evidence for variant in matched normal sample,
number of mutant reads, and mutant allele ratio. The statistical
frameworks to encompass all of these factors into a single model
and metric are still being developed. Some single-sample SNP
callers give a p-value that purely reflects the likelihood for the
presence of a non-reference allele. Furthermore, most mutation





variants Indels Statistical method Reference
qSNP X X empirically determined set of heuristics optimized
for sensitivity in low purity tumors
present study
GATK n/a X Bayesian model for genotype likelihood, can take into
account multiple samples for calibration
[7]
Strelka X X Bayesian model of tumor as a mixture of normal sample
with somatic variation
[8]
SomaticSniper X X Bayesian comparison of genotype likelihoods based
on MAQ genotype model
[9]




VarScan2 X X X heuristics to determine genotypes and Fisher’s exact
test to examine read count differences, also outputs
CNV regions for exome data
[10]
SNVMix n/a probabilistic binomial mixture model accounting for
tumor ploidy and purity
[11]
doi:10.1371/journal.pone.0074380.t001
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calling software is used in combination with a series of post-calling
filtering steps to remove likely false positives. This practice means
that the original p-values calculated by the mutation caller are
overridden by these further checks that ultimately decide whether
or not a mutation is considered high confidence. For low purity
tumors, Poisson sampling of alleles can confound estimates of their
true frequencies, further compromising the calculation of accurate
p-values or resulting in positions not exceeding a likelihood
threshold.
For these reasons we have not made an attempt to estimate a
p-value upfront but instead use flags to indicate that a putative
somatic mutation call does not meet certain quality criteria or
evidence thresholds (Table 3). For example, putative somatic
positions are checked for the presence of the variant in the
matched normal BAM. If a position has evidence in the normal,
the call is annotated as such. Somatic positions are further
checked for being a germline variant in another patient as this
can indicate under-sampling of alleles in the matched normal.
For this check, we use an in-house database of germline variants
and qSNP can be set up to output high quality germline calls to
this database with each iteration of qSNP. Positions that pass all
checks are considered to be of highest confidence and we expect
these to be true somatic events. They are annotated as PASS in
the qSNP output. Positions where the normal sample lacks
adequate sequencing coverage are potentially false positive
somatic calls and may return germline in verification. These are
annotated as COVN12 in qSNP output. All remaining somatic
mutations such as those where there is evidence of the variant
also in the normal sample or where only few mutant reads
support the variant call are considered lowest confidence and
are expected to include many false positives. These calls are
annotated as outlined in Table 3.
Output mutation calls in.vcf and DCC formats
Output in Variant Call Format (VCF) [16] was required as
VCF is becoming the standard format for mutation reporting and
annotation and allows integration with an ever-expanding set of
VCF tools. To enable easy integration with the International
Cancer Genome Consortium (ICGC) Data Coordination Centre
(DCC), output in DCC format was also implemented.
Fast, easy to run and operating-system independent
Given the continuously increasing throughput of next-genera-
tion sequencing platforms, qSNP needed to be efficient in its use of
compute resources. To achieve this, qSNP is implemented in
JAVA using the Picard library (version 1.62). qSNP is driven by a
single plain-text configuration file in the ‘‘Windows INI-file’’ style
and takes as its primary inputs, a pair of tumor and normal BAM
files that have been duplicate-marked and coordinate-sorted.
qSNP implements a fast and flexible read-filtering system and if
filters such as minimum mapping quality or alignment length are
specified, qSNP will filter out failing reads prior to analysis. qSNP
creates a pileup of bases in tumor and normal to look for evidence
of a variant. qSNP has been specifically designed to make use of a
compute cluster. It is thus multi-threaded, requiring 5 cores and
20 GB of memory to run efficiently.
Tuning using verification data
To identify common error sources and to refine qSNP,
extensive verification of 3,253 putative somatic mutation calls
was performed across 65 tumors of 6 to 83% purity (mean 38%
purity), including 60 tumors reported in Biankin et al. [14]
(Table 4, Table S1). In total, 717 mutations were confirmed as
true somatic events, of which 704 had been classified as PASS
by qSNP (Table 4). Miscalled somatic mutations were most
commonly associated with one of three features: position in
regions of sequence homology, support only by non-indepen-
dent reads or support by low evidence. By designing strategies
to eliminate false positives associated with these common error
sources, we were able to maintain an accuracy of 57% at a
sensitivity of 98% across these tumors of mean purity of 38%
(Table 4). This sensitivity is likely an overestimate of the true
sensitivity as only known, verified mutations called by qSNP at
any evidence threshold were chosen for verification; it is
possible that there were additional somatic events that were
never called. Nevertheless, our strategy is successful in
retaining the vast majority of known true positive events
(98%), while eliminating false positive calls associated with
common error sources.
Sequence homology regions
Regions of sequence homology can cause problems in mapping
and reads may be erroneously mapped to the wrong homologue.
This is not always apparent from the mapping quality values that
can remain high especially if these values reflect pairing quality
values that consider the mapping qualities of both reads in a read
pair. Nevertheless, these regions can often be identified on the
basis of having an excess of putative sequence variants. To
Table 2. Classification of germline and somatic events.
Normal genotype Tumor genotype Details* Classification
Hom Het Variant is reference allele; G/G.A/G Germline1
Hom Het Variant novel; A/A.A/G Somatic1
Het Hom Tumor allele same; A/G.G/G Germline2
Het Hom Tumor allele different; A/G.T/T Somatic
Hom Hom Same; G/G.G/G Germline
Hom Hom Different; A/A.G/G Somatic
Het Het Same; A/G.A/G Germline
Het Het Different; A/G.T/G Somatic
*All examples assume ‘A’ as the reference allele, ‘G’ as the variant, and ‘Hom’ and ‘Het’ denote homozygous and heterozygous respectively.
1check coverage in normal to exclude under-calling.
2could indicate LOH in tumor.
doi:10.1371/journal.pone.0074380.t002
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overcome this challenge, qSNP has a user-defined BAM filtering
option so that only high quality reads will trigger a mutation call.
For SOLiD v4 data, mapped with Bioscope 2.1 we find the
following filters useful:
1) min. 35 bp alignment length or (second of read pair and
mapped as a proper pair);
2) min. SM.15 (single mapping quality);
3) no more than 2 base-space mismatches to the reference;
4) not a PCR duplicate (Picard MarkDuplicates).
For Illumina 100 bp paired-end data mapped with BWA, we
use the following filters:
1) min. SM.10 (single mapping quality);
2) no more than 3 mismatches to the reference;
3) not a PCR duplicate (Picard MarkDuplicates).
These read filters can be specified in the qSNP configuration file
using a domain-specific language (DSL). Once a somatic mutation
call has been made, the unfiltered non-duplicate pileup from the
normal BAM is checked to see if there is any evidence of the
variant. These steps help eliminate many of the false positives
associated with this common error source.
Non-independent reads
Picard MarkDuplicates (http://picard.sourceforge.net.) has
become the standard tool for identifying PCR duplicates in
next-generation sequencing data. Given that PCR is commonly
used to amplify DNA for sequencing, likely PCR duplicates
need to be identified so they don’t inflate allele counts during
mutation calling. To identify duplicates Picard MarkDuplicates
uses the start coordinates and orientations of both reads of a
read pair. Within a set of duplicate read pairs, the read pair with
the highest base qualities is retained with the others marked as
PCR duplicates. Picard MarkDuplicates does not consider the
sequence of the reads, only the alignment start coordinates and
orientations.
This strategy of marking PCR duplicates has one drawback.
Read pairs where one read maps to a region of sequence
homology sometimes fail to pass the Picard test for being PCR
duplicates because these reads often map to different copies of
the region of sequence homology, thus disguising the fact that
they are indeed all derived from the same PCR molecule. These
reads can be easily identified upon visual inspection in
Integrative Genomics Viewer (IGV) [17,18] on the basis of
shared start coordinates of one read partner with different
chromosome map positions of the other read in the pair
(Figure 1). To overcome this challenge, all putative somatic
Table 3. Post-processing checks performed by qSNP.
Annotation Variant type Description
PASS Somatic, Germline (Passed all post-processing checks) AND (min 5 mutant reads) AND (min 4
novel starts not considering read pair)
COVN12 Somatic Less than 12 reads coverage in matched normal sample
COVN8 Germline Less than 8 reads coverage in matched normal sample
SAN3 Germline Less than 3 reads of same allele in normal
COVT8 Germline Less than 8 reads coverage in tumor
SAT3 Germline Less than 3 reads of same allele in tumor
GERM Somatic Mutation is a germline variant in another patient
MIN Somatic Mutation also found in pileup of normal BAM
MIUN Somatic Mutation also found in pileup of unfiltered normal BAM
NNS Somatic, Germline Less than 4 novel starts not considering read pair
MR Somatic, Germline Less than 5 variant reads
MER Somatic Mutation same as reference
SBIAS Somatic Strand bias (Illumina only)
doi:10.1371/journal.pone.0074380.t003
Table 4. Details of verification using amplicon-based sequencing on the Ion Torrent.
Verification across65primary pancreatic adenocarcinomas with mean
tumor purity 38% (range 6 to 83%)
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mutation calls are annotated in qSNP with the number of novel
read starts not considering the read pair (NNS in the VCF output files).
Based on our extensive verification data, we find that a
minimum of 4 novel starts using this criterion is a useful lower
limit for somatic mutation detection.
Low evidence calls
Finally, mutation calls that are only supported by a few mutant
reads are also common false positives. However, as tumor purity
decreases, so does the expected mutant allele ratio, making it
difficult to distinguish true somatic events from sequencing
artifacts. We investigated a number of criteria to improve signal
to noise for calls with low evidence. Strand bias proved not to be a
useful discriminating feature for SOLiD v4 data as many true
somatic mutations were only supported by reads on one strand.
Using results from amplicon-based verification, 363 FP were only
on one strand, 171 FP were on both strands, 94 TP were only on
one strand, and 610 TP were on both strands. Filtering somatic
mutation calls by requiring the mutant allele being represented by
reads on both strands will thus severely impact sensitivity of
detection. Mutant allele ratio, i.e. proportion of mutant reads, also
had poor discriminating power with many true positive calls
having very low mutant allele ratios: 112 FP had a mutant allele
ratio ,10%, 422 FP had a mutant allele ratio .10%, 130 TP had
a mutant allele ratio ,10% and 574 had a mutant allele ratio
.10%.
In contrast, there was a strong positive relationship between the
likelihood of being a true somatic event and the number of reads with
novel starts not considering the read pair supporting the mutation. The
higher the number of mutant reads supporting the call, the higher
the accuracy. There is a trade-off between sensitivity and
accuracy, however. At 5 mutant reads with a minimum of 4
novel starts not considering read pair, we obtain an average
accuracy of 57% and sensitivity of 98% (Table 4), which we found
useful thresholds for mutation detection and follow-up verification
in primary pancreatic adenocarcinomas. By requiring a minimum
of 10 mutant reads, our accuracy increases to 94%, but at the cost
of reduced sensitivity (53%). These criteria were determined using
exome samples that had been sequenced to a depth where 80% of
targeted bases had at least 206 coverage (average targeted base
coverage of approximately 656).
Benchmarking variant calling in a controlled mixture
experiment
We previously modeled the performance of qSNP in a panel of
mixtures where a pancreatic adenocarcinoma cell line and its
matched normal were mixed at the following proportions: 0, 10,
20, 40, 60, 80 and 100% cell line DNA [14]. These mixtures were
sequenced to an average depth of approximately 656 using the
SureSelect exon capture method and SOLiD v4 sequencing. Here,
we compare the decay in sensitivity across these mixtures using
variant calls from qSNP and GATK (Table 5). All somatic qSNP
calls made in the 100% cell line sample were selected for
verification by amplicon-based sequencing on the Ion Torrent
PGM. The remaining mutation calls were assessed for evidence on
an alternate sequencing platform - HiSeq 2000 for calls made on
the SOLiD v4 platform and vice versa. A position was considered
verified if read depth was at least 206and the mutation occurred
at a frequency of at least 5% with a minimum of 3 variant reads on
the alternate sequencing platform. In all following comparisons,
GATK and Strelka were run in default mode with no changes to
default parameters. qSNP was run in standard mode, requiring a
minimum of 3 mutant alleles of the same type to make a variant
call prior to applying standard read annotations and post-calling
filters as described in the text.
As expected, as purity decreased, so did the sensitivity of
detecting true positive somatic mutations. In total, 84 mutations
were verified as true somatic events. At 40% tumor purity, qSNP
successfully called 57 of 84 (68%) verified somatic mutations with
only 1 false positive call (Table 5). At tumor purities of 20% and
10% the sensitivity of detection dropped to 42% and 15%,
respectively. By increasing sequencing depth to .1506, the
sensitivity of detection in the 20% and 10% samples was
improved, but not to a level comparable to that observed in the
higher mixtures (Table 5). In comparison, the GATK pipeline
called only 50 of 84 (60%) of verified somatic events in the 100%
sample and decayed more rapidly as tumor purity decreased with
no successful mutation calls in the 10% mixture (Table 5).
In addition, we re-sequenced 5 of these mixtures to an average
depth of 486 on HiSeq 2000 and called mutations using qSNP,
GATK and Strelka (Table 6). qSNP detected a greater number of
verified somatic events than GATK or Strelka in all mixtures
(Table 6). Here, a total of 92 mutations were verified as true
Figure 1. Non-independent reads confounding mutation calls. Read pairs are colored by the chromosome map position of the second read
in the pair. MarkDuplicates fails to correctly identify these non-independent read pairs as PCR duplicates due to the different map locations of the
second read.
doi:10.1371/journal.pone.0074380.g001
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somatic events. At 40% tumor purity, qSNP successfully called 60
of 92 (65%) of verified somatic mutations, compared to GATK
that called 55 (60%), and Strelka that called 56 (61%) verified
somatic mutations (Table 6). There was substantial overlap in true
positive somatic calls between the three callers; 68 of a total of 90
(76%) verified somatic mutations were called by all three software
tools (Figure 2). These positions had an average of 32 mutant reads
with an average mutant allele fraction of 0.52 (range 0.12 to 0.93).
As tumor purity decreased, so did the number of mutations called
by all three software tools (Figure 2). There were no mutations
unique to GATK and Strelka that were not also called by qSNP
and for all mixtures qSNP missed the fewest number of true
somatic events compared to the other two callers. qSNP and
GATK further called 1 private somatic mutation each that was not
detected by the other callers, while Strelka called 7 private somatic
mutations undetected by the other callers (Figure 2).
COLO-829 whole-genome benchmarking study
The melanoma cell line COLO-829 [4] has been used
previously for benchmarking new cancer analysis tools [8,9]. An
aliquot of cell line and matched normal DNA were received and
whole-genome sequencing was performed on both SOLiD v4 (avg.
coverage 326) and HiSeq 2000 (avg. coverage 756). The
performance of qSNP was benchmarked against calls previously
published by the Wellcome Trust Sanger Institute (WTSI) that
included 454 verified somatic mutations, 43 mutations previously
reported in COSMIC and 32,842 untested calls [4]. On the
SOLiD v4 platform qSNP called 85% of the 454 previously
verified somatic mutations as well as 25 novel mutations that were
verified using amplicon-based sequencing on the Ion Torrent
platform (Table 7, Table S2). For untested calls there was
considerable overlap between those reported by Pleasance et al. [4]
and this study. For all variants called and verified by WTSI but not
called by qSNP, a detailed breakdown is provided showing why
the call was not made. For example, positions with insufficient
coverage in the matched normal and which thus did not pass the
qSNP PASS criterion are tabulated as well as positions where we
observed evidence in the matched normal sample. The majority of
positions where qSNP failed to make a call (5,735 or 62% of
positions only called by WTSI) had less than 3 reads evidence in
our SOLiD v4 sequence data.
Using the HiSeq 2000 sequence data, qSNP called 85% of 454
previously reported verified somatic mutations and 26 novel
mutations that were verified by Ion Torrent amplicon sequencing
(Table 7). Of the positions initially reported by Pleasance et al. [4],
the two re-sequencing efforts on SOLiD v4 and HiSeq 2000
identified 3531 positions that had less than 3 reads evidence for a
mutant allele on both platforms (Table 7). On both platforms
qSNP called a significant number of private mutations, 6486 on
SOLiD v4 and 13098 on HiSeq 2000 of which 2674 were called
on both platforms.
Germline variants
While qSNP was designed primarily to identify somatic
mutations, a comparison of resulting germline calls was made
using the COLO-829 sample and calls made by the Illumina
Human 1M OmniQuad arrays, selecting all positions from the
arrays that showed evidence of a non-reference allele and had a
GenCall (GC) score of .0.7. The average genotype concordance
Table 5. Controlled mixture experiment to assess the effect of reducing tumor purity on somatic mutation detection using the
SOLiD v4 platform.
Mixture (%tumor) Cov. 80% Mean cov. qSNP GATK*
VS‘ FP‘ U‘ VS‘ FP‘ U‘
100 176 62.16 84 17 2 50 7 1
80 196 72.13 73 5 10 49 1 2
60 186 67.49 66 6 6 45 0 4
40 196 67.67 57 1 8 38 0 3
20 236 81.96 35 3 2 15 0 1
10 226 79.35 13 5 5 0 0 1
20 496 161.11 48 5 6 18 0 8
10 476 152.11 15 4 5 0 0 8
*raw.vcf files were passed through qSNP post-processing checks outlined in Table 3 to remove likely false positives such as positions with evidence in the matched
normal.
‘VS verified somatic; FP false positive; U untested.
doi:10.1371/journal.pone.0074380.t005
Figure 2. Overlap in somatic mutation calls. Verified somatic
mutation calls were compared across three callers in 5 different tumor
purity mixtures. Values are number of calls in 100%, 80%, 60%, 40% and
20% tumor content mixture, from top to bottom.
doi:10.1371/journal.pone.0074380.g002
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at positions with at least 8 reads coverage was 95% (same genotype
call), while the variant call concordance was 99% (Table S3). As
sequence depth increased so did accuracy in making the correct
genotype call. Positions with .706 sequence coverage had a
genotype concordance of 99% and a variant call concordance of
100% (Table S3). The array data has been submitted to Gene
Expression Omnibus (GEO), accession number GSE47904.
Discussion
The development of cancer genome analysis tools and somatic
mutation calling software is an active area of research, but the
effects of reduced tumor purity on somatic mutation calling still
remain largely unexplored. Here, we present a strategy for somatic
point mutation calling in low purity tumors. We have used
extensive verification in primary pancreatic adenocarcinoma
samples to determine a variant calling strategy that controls the
false positive rate while maximizing sensitivity. When directly
assessing the accuracy and sensitivity of our approach in a
controlled mixture experiment where samples of varying purity
were generated and sequenced, we demonstrate superior perfor-
mance compared to other commonly used somatic mutation
callers, for both SOLiD v4 and HiSeq 2000 data. Finally, we have
benchmarked our caller against the COLO-829 sample and show
substantial overlap with previously published calls and calls made
by either the SOLiD v4 or HiSeq2000 platforms as well as a small
number of previously undetected protein-coding somatic muta-
tions.
In the controlled mixture experiment the single sample
approach used by GATK had reduced overall sensitivity and a
faster decay curve across samples of decreasing tumor purity than
the joint sample callers, qSNP and Strelka, consistent with
previous reports that joint sample analyses perform better for
cancer analysis [9]. Using SOLiD v4 sequence data, qSNP and
GATK both achieved a low false positive rate, although GATK
called only 60% of known true positives in the 100% purity
mixture. Using the HiSeq 2000 platform, the sensitivity of GATK
was improved, but at the cost of a high total number of calls likely
due to a high false positive rate that was only improved by
applying the same post-processing checks as in the qSNP pipeline,
such as excluding positions that had evidence of the mutation in
the matched normal sample (Table 3).
The controlled mixture experiment further compared our
heuristic caller to a Bayesian approach (Strelka), demonstrating a
marginal advantage in sensitivity and false positive rate for qSNP.
We believe that the success of our heuristic caller is due to its
ability to use minimum evidence to trigger a somatic mutation call
and the use of powerful post-processing checks that control the
Table 6. Controlled mixture experiment to assess the effect of reducing tumor purity on somatic mutation detection using the
HiSeq2000 platform.
Mixture (%tumor) Cov. 80% Mean cov. qSNP GATK* Strelka**
VS‘ FP‘ U‘ VS‘ FP‘ U‘ VS‘ FP‘ U‘
100 266 61.43 82 1 72 80 1 72 77 1 66
80 196 43.05 77 0 60 76 0 57 75 2 57
60 176 40.57 65 1 45 62 1 39 60 2 44
40 186 43.36 60 0 45 55 0 30 56 1 45
20 226 51.83 47 0 22 37 0 14 48 1 26
*.vcf files were passed through qSNP post-processing checks outlined in Table 3 to remove likely false positives such as positions with evidence in the matched normal.
**calls from ‘pass’ category.
‘VS verified somatic; FP false positive; U untested.
doi:10.1371/journal.pone.0074380.t006
Table 7. Benchmarking qSNP on sequencing data from the SOLiD v4 and HiSeq 2000 platforms using COLO-829 variants verified
by either WTSI (WTSI only, qSNP+WTSI) or QCMG (qSNP only).
Caller Details SOLiD v4 HiSeq 2000 SOLiD v4 and HiSeq 2000
VS‘ C‘ U‘ VS‘ C‘ U‘ VS‘ C‘ U‘
qSNP+WTSI 381 33 23,544 385 39 23,660 333 30 19,276
WTSI only ,126 coverage in normal 18 5 1,329 0 0 104 0 0 26
mutation also in normal 8 0 455 19 2 1,105 0 0 19
germline in another patient 0 0 7 1 0 6 0 0 5
did not pass post-filters 16 1 1,548 24 0 1,623 1 0 86
qSNP germline call 0 0 24 0 0 63 0 0 10
no call - ,3 reads evidence 0 0 5,735 22 2 5,945 0 0 3,531
no call - other 31 4 200 3 0 336 2 0 0
qSNP only* 25 0 6,486 26 0 13,098 22 0 2,674
*min 5 mutant reads and 4 novel starts not considering pair.
‘VS verified somatic; C cosmic; U untested.
doi:10.1371/journal.pone.0074380.t007
Novel Somatic Mutation Calling Strategy
PLOS ONE | www.plosone.org 7 November 2013 | Volume 8 | Issue 11 | e74380
false positive rate. Machine learning approaches such as the
classifier of Ding et al. [6] can be a powerful strategy for identifying
features discriminating true positive from false positive mutation
calls, provided availability of orthogonal verification data for
training of the classifier. Discriminant features can then be
incorporated in the set of heuristics for informing mutation calls.
In addition, automated pipelines for amplicon-based verification
can be set up using smaller scale sequencers such as the Ion
Torrent or MiSeq platform. We have found this a successful
strategy in pancreatic adenocarcinomas that vary widely in tumor
purity. On the other hand, Bayesian approaches may be more
readily transferrable across datasets and provide some form of
quantitative measure of the confidence for a given mutation call,
although as discussed above these will be most useful for high
coverage regions and tumors of high purity where allele
distributions can be accurately estimated and are not confounded
by Poisson sampling effects.
Finally, the controlled mixture experiment demonstrated that
no single variant calling strategy is optimal in all aspects. While
there was good overlap between callers and the majority of calls
were made by at least 2 callers, each caller also identified private
mutations not called by the others and which were verified as
somatic. Different callers thus have unique benefits, although
qSNP missed the fewest number of true somatic events. These
comparisons show that there is further scope for refinement of
either mutation calling strategy to improve accuracy and
sensitivity. Where high-density SNP array data are available, we
recommend use of a genomic tool for estimating tumor purity
prior to variant calling, such as the qPure software [19].
Determining the purity of a tumor will help identify the most
useful thresholds for variant calling. For example, samples of high
purity are expected to have a lower false negative rate and thus the
stringency of variant calling may be increased to lower the false
positive rate. Given that the qSNP analysis of a whole-exome
dataset of tumor/matched normal takes only 30 minutes, multiple
different parameters can be easily trialled to assess their effect on
the total number of calls.
We used the COLO-829 sample for benchmarking both
germline and somatic mutation calls. Germline calls from qSNP
were compared to those made on the Illumina 1M OmniQuad
chip, showing that the variant call concordance was over 99%
even for positions with only 8 reads coverage. As sequencing depth
increased, so did our accuracy to make the correct genotype call.
Detailed comparisons of the qSNP somatic mutation calls against
the original GAIIx calls of Pleasance et al. [4] showed considerable
overlap for re-sequencing data from both the SOLiD v4 and
HiSeq 2000 platforms, although there were also some important
differences. For example, our re-sequencing efforts identified 3,531
positions that had less than 3 reads evidence for a mutation in both
the SOLiD v4 and HiSeq 2000 data, suggesting that these original
calls are false positives and may reflect differences in read
sampling, mapping or bias of the original sequencing platform.
Similarly, calls private to the qSNP pipeline on either the SOLiD
v4 or HiSeq 2000 platform likely included a large number of false
positive calls as evidenced by the fact that only 2,674of these
positions unique to our datasets were called on both sequencing
platforms. Our calls on the HiSeq 2000 platform appear noisier
judging by the total number of private calls on this platform
(13,098) compared to calls on the SOLiD v4 platform (6,486). This
is likely due to the increased coverage in the HiSeq runs (756
average base coverage compared to 326 in the SOLiD v4 data),
which is expected to result in more variant calls when using the
same evidence thresholds. We are currently implementing and
refining post-processing checks for use with HiSeq whole-genome
datasets that are adjusted for coverage and exclude common error
sources, such as calls made in repeat regions, low complexity
sequence or near indels. These post-filters are becoming increas-
ingly important as analyses are moving from exon-capture to
whole-genome sequencing datasets. Nevertheless, the large overlap
in calls between the original and the two re-sequencing datasets
suggests that the overall sensitivity of detection of qSNP was good,
and that the remaining challenge lies in controlling platform- and
software-specific error sources.
Conclusions
Accurate and sensitive somatic mutation in low purity tumors
remains a formidable challenge, but one of great interest to the
study of many solid tumors. Here, we have discussed some of the
key challenges in this field and strategies we have devised to handle
these. Continuous refinement of existing strategies be they
heuristics or Bayesian, as well as comparative analyses and
benchmarking on a defined set of samples will be critical to further
improve performance of current somatic mutation callers.
Materials and Methods
Samples
Primary pancreatic adenocarcinoma samples discussed in this
study were accrued as part of the Australian Pancreatic Genome
Initiative (APGI) (http://www/pancreaticcancer.net.au) using an
institutional approved process for consent. COLO-829 sample
aliquots for the melanoma cell line and matched normal were
obtained from WTSI. Sample extraction and processing followed
those outlined in Biankin et al. [14].
Verification of somatic mutations
Verification of somatic mutation calls was performed by
targeted Ion Torrent sequencing using PCR primers to amplify
70–150 bp amplicons overlapping the somatic mutation. Tumor
and normal DNA was whole-genome amplified prior to PCR
using the Illustra GenomiPhi V2 DNA Amplification Kit (GE; 25-
6600-30). PCR reactions and sequencing was performed as
outlined in Biankin et al. (2012). Briefly, PCR reactions were set
up using 10 ng of amplified gDNA and 5 uM of primers mix. Ion
Spheres were generated using the Ion Xpress Template Kit (Life
Technologies; 4469001) with approximately 260 million amplicon
molecules per emulsion PCR, effectively yielding an emulsion
containing 1 amplicon molecule per Ion Sphere. Samples were
sequenced using the Ion Sequencing Kit (Life technologies;
4468997) and the Ion Chip 316 Kit (Life Technologies; 4469496).
Verification of somatic mutations was performed by sequence
pileup at each mutant position and a position was considered
verified if it has a minimum depth of 100 reads coverage in the
tumor and normal, a mutant allele frequency of at least 10% in
tumor and less than 0.5% in normal.
Controlled mixture experiment
SOLiD exon capture data for the mixture experiment was taken
from Biankin et al. [14].
Illumina exon capture was performed using the TargetSeq
Exome Enrichment System (Life Technologies; A14060 and
A138230) according to the manufacturer’s instructions, however
some modifications were made to the protocol to make the kit
compatible with Illumina libraries. SOLiD blocking and PCR
oligos were replaced with Illumina TruSeq blocking and PCR
oligos derived from the NimbleGen SeqCap EZ Library SR User’s
Guide v3.0 (Roche; 06588786001). The captured libraries were
Novel Somatic Mutation Calling Strategy
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washed on the Life Techologies Library Builder using an
unreleased protocol (Life Technologies), and the final post-
capture PCR used the protocol in the NimbleGen SeqCap EZ
Library SR User’s Guide v3.0 (Roche; 06588786001). The final
captured libraries were run on the Agilent BioAnalyser 2100
using the DNA High Sensitivity Kit (Agilent; 5067-4626) to
calculate the molarity and assess the size distribution. Cluster
generation of the libraries was performed using the TruSeq PE
Cluster Kit v3-cBot-HS (Illumina; PE-401-3001), and sequenc-
ing carried out. The SOLiD and HiSeq.BAM files have been
submitted to the European Genome Archive, as part of project
EGAS00000000078.
COLO-829 whole-genome benchmarking study
Whole-genome sequencing of the COLO-829 tumor and
matched normal sample were performed using the SOLiD v4
and Illumina HiSeq 2000 sequencing platforms. For preparation
of SOLiD v4 long mate-pair libraries, 13 mg of gDNA was
sheared to a mean size of 2.5 kb using the Covaris S2 system.
Shearing was completed using the Blue miniTUBEs (Covaris p/
n: 520065) using the standard settings for 3 kb as described in
Covaris protocol 400069 (http://http//covarisinc.com/wp-
content/uploads/pn_400069.pdf). Following shearing, 1 uL of
sheared sample was run on the Agilent BioAnalyser2100 using
the DNA High Sensitivity Kit (Agilent p/n: 5067-4626) to assess
the shearing size and distribution. The entire sheared DNA
sample was then converted into a SOLiDH compatible Long
Mate Pair (LMP) library using Life Technologies 5500SOLiDH
Mate-Paired Library Kit (Invitrogen p/n: 4464418) following
the standard protocol (http://tools.invitrogen.com/content/sfs/
manuals/cms_093442.pdf) with 10 minutes nick translation and
a total of 12 cycles of amplification for the final library. After
PCR amplification the libraries were assessed for molarity and
size distribution using the Agilent BioAnalyser 2100 using the
DNA High Sensitivity Kit. Libraries that passed this QC were
prepared for SOLiDH sequencing.
For the preparation of Illumina DNA libraries, 1 mg of
gDNA was sheared to a mean size of 300 bp in a 130 mL
volume using a Covaris microTUBE and the Covaris S2 system
according to the standard protocol (Covaris; 010158 Rev C).
The sheared sample was prepared into a library using the
NEBNext DNA Library Prep Master Mix Set for Illumina
(NEB; E6040S) according to the manufacturer’s instructions
with modifications. Size selection was done using an agarose
gel (3% agarose) instead of the AMPure XP Beads size
selection. The final libraries were run on the Agilent
BioAnalyser 2100 using the DNA High Sensitivity Kit (Agilent;
5067-4626) to calculate the molarity and assess the size
distribution. Libraries were then prepared for Illumina cluster
generation and sequencing.
Of the qSNP unique calls, 61 protein-coding positions were
selected for verification on the Ion Torrent platform using the
same verification criteria as outlined above; 30 were confirmed as
true somatic events and 31 as false positives (Table S2). In
addition, 3 somatic mutations originally identified by WTSI could
not be confirmed as somatic events in our verification efforts
(Table S2).
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